Genomic profiling of GBM has characterized alterations in core signaling pathways connected with CDK, such as inactivation of the CDKN2 locus (50%) encoding the CDK4/6 inhibitor p16INK4 and the amplification of CDK4 (13%) and CDK6 (1.5%) [81]. The gene discussed is CDK6; the disease is glioblastoma.